tafluprost (zioptan) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Tafluprost acid is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Studies in animals and humans suggest that the main mechanism of action is increased uveoscleral outflow. A prostaglandin analogue ester prodrug used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. Tafluprost was approved for use in the U.S. on February 10, 2012. Tafluprost, preserved and preservative-free formulations, received marketing approval for the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension in several European and Nordic countries as well as Japan, and some other Asia Pacific markets.   NCATS

Chemistry

  • SMILES: CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC2=CC=CC=C2
  • InChIKey: WSNODXPBBALQOF-VEJSHDCNSA-N
  • Mol. Mass: 452.5313
  • ALogP: 4.68
  • ChEMBL Molecule:
    tafluprost  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Topical
  • Pro Drug: Yes

Drug Pricing (per unit)

United States

$6.8149

Australia

$17.5450
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1-methylethyl (5z)-7-((1r,2r, 3r,5s)-2-((1e)-3,3-difluoro-4-phenoxy -1-butenyl)-3,5-dihydroxycyclopentyl)-5-heptenoate | afp-168 | mk-2452 | saflutan | taflotan | tafluprost | tafluprost ophthalmic solution | tapros | zioptan

Organizations (31)

Research & Development (26)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (3)


 

Glaucoma (approved 2012)

Glaucoma, Open-Angle

Ocular Hypertension

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Corneal Diseases (Phase 4)

Glaucoma ()

Glaucoma, Open-Angle (Phase 4)

Graves Ophthalmopathy (Phase 4)

Healthy Volunteers (Phase 1)

Ocular Hypertension (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 28
  • # of Trial Organizations: 26

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue